Haemophilia B Leyden in Greece

Summary

In this paper, a five generation Greek family is described with haemophilia B. The disease is characterized by a normal ox-brain prothrombin time, normal levels of the vitamin-K dependent clotting factors VII and X and a proportional reduction of factor IX acttivity and antigen levels all of which is consistent with the cross-reacting material negative form of haemophilia B. However, in this family the factor IX levels in the three patients of generation V are around 1 U/dl while the three older patients in generation III have factor IX levels ranging from 28 to 44 U/dl. In the oldest patient of generation V we observed a rise of the factor IX level from 1 U/dl up to the age of 13 to 10 U/dl at age 14. In addition, the older patients have very mild bleeding symptoms or none at all, while the young ones have occasional spontaneous haemorrhages in muscles and joints, compatible with severe or moderately severe haemophilia. The disease appears to be similar to haemophilia B Leyden which has been described in a Dutch family.

Key words

Haemophilia B - Puberty - Factor IX - Coagulation factors Summary

• References

• 1 Giannelli F, Choo KH, Rees D JG, Boyd Y, Rizza CR, Brownlee GG. Gene deletions in patients with haemophilia B and anti-factor IX antibodies. Nature 1983; 303: 181-182
• 2 Peake IR, Furlong BL, Bloom AL. Carrier detection by direct gene analysis in a family with haemophilia B (factor IX deficiency). Lancet 1984; 2: 242-243
• 3 Noyes CM, Griffith MJ, Roberts HR, Lundblad RL. Identification of the molecular defect in factor IX Chapel Hill. Substitution of histidine for arginine at position 145. Proc Natl Acad Sci USA 1983; 80: 4200-4202
• 4 Davis IM, McGraw RA, Graham JB, Roberts HR. Identification of the genetic defect in factor IX Alabama; DNA sequence analysis reveals a Gly substitution for Asp⁴⁶ . Blood 1984; 64: 262a
• 5 Veltkamp JJ, Meilof J, Remmelts HG, van der Vlerk D, Loeliger EA. Another genetic variant of Haemohilia B: Haemophilia B Leyden. Scand J Haematol 1970; 7: 82-90
• 6 Briët E, Bertina RM, van Tilburg NH, Veltkamp JJ. Haemophilia B Leyden. New Engl J Med 1982; 306: 788-791
• 7 Briët E, van Leeuwen-Comelisse ISJ, van der Vlerk D, van Tilburg NH. Hemofilie B Leyden. Ned Tijdschr Geneeskd 1986; 130: 1324-1327
• 8 Owren PA. A quantitative one-stage method for the assay of prothrombin. Scand J Clin Lab Invest 1949; 1: 81-83
• 9 Milstone JH. The problem of the lipid thromboplastins. Yale Journal of Biol Med 1950; 22: 765-768
• 10 Bertina RM, van der Linden IK. Inhibitor neutralisation assay and electro-immuno assay of human factor IX (Christmas Factor). Clin Chim Acta 1977; 77: 275-286
• 11 Hougie C, Twomey JJ. Haemophilia B_m: a new type of factor-IX deficiency. Lancet 1967; I: 698-700
• 12 Chung KS, Bezeaud A, Goldsmith JC, McMillan CW, Ménaché D, Roberts HR. Congenital deficiency of blood clotting factors II, VII, IX and X. Blood 1979; 53: 776-787
• 13 Briët E, Wijnands MC, Veltkamp JJ. The prophylactic treatment of hemophilia B Leyden with anabolic steroids. Ann Intern Med 1985; 103: 225-226